Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Toray Industries, Inc | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MP-424+RBV+IFN beta, Genotype1 | Experimental |
| |
| RBV+IFN beta, Genotype1 | Experimental |
| |
| MP-424+RBV+IFN beta, Genotype2 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MP-424 | Drug | MP-424: 750mg every 8 hours (q8h) for 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) | 72 weeks(RBV+IFN beta), 48 weeks(MP-424+RBV+IFN beta) |
| Measure | Description | Time Frame |
|---|---|---|
| Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response) | 4 weeks | |
| Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response) | 48 weeks(RBV+IFN beta), 24 weeks(MP-424+RBV+IFN beta) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kazuoki Kondo, M.D. | Tanabe Pharma Corporation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Toranomon Hospital | Kawasaki | Takatsu-ku | 213-8587 | Japan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28497489 | Result | Kumada H, Mochida S, Nakamuta M, Suzuki F, Yagi T, Takasaki R, Okai M, Kamiya N, Okada Y, Hirota S, Orihashi M, Ochi M, Chayama K. Efficacy and safety of telaprevir with natural human interferon-beta and ribavirin in Japanese chronic hepatitis C patients with depression. Hepatol Res. 2018 Feb;48(2):184-192. doi: 10.1111/hepr.12914. Epub 2017 Jul 19. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | MP-424+RBV+IFN Beta, Genotype1 | Drug: MP-424 MP-424: 750mg every 8 hours (q8h) for 12 weeks Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 24 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 24 weeks |
| FG001 | RBV+IFN Beta, Genotype1 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| RBV(24 weeks) | Drug | RBV: 600 - 1000mg/day based on body weight for 24 weeks |
|
| IFN beta(24 weeks) | Drug | IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks |
|
| RBV(48 weeks) | Drug | RBV: 600 - 1000mg/day based on body weight for 48 weeks |
|
| IFN beta(48 weeks) | Drug | IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks |
|
| Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration | 60 weeks(RBV+IFN beta), 36 weeks(MP-424+RBV+IFN beta) |
| Transition of Serum HCV RNA Levels | Baseline，Day2，Day3，1Week，2Weeks，3Weeks，4Weeks，12Weeks，End of treatment，Follow-up 12weeks，Follow-up 24weeks |
| Number of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV. | To examine the emergence of resistance-associated variants after MP-424 administration. | From baseline to 24 weeks after completion of drug administration |
Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 48 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 48 weeks |
| FG002 | MP-424+RBV+IFN Beta, Genotype2 | Drug: MP-424 MP-424: 750mg every 8 hours (q8h) for 12 weeks Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 24 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 24 weeks |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | MP-424+RBV+IFN Beta, Genotype1 | Drug: MP-424 MP-424: 750mg every 8 hours (q8h) for 12 weeks Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 24 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 24 weeks |
| BG001 | RBV+IFN Beta, Genotype1 | Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 48 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 48 weeks |
| BG002 | MP-424+RBV+IFN Beta, Genotype2 | Drug: MP-424 MP-424: 750mg every 8 hours (q8h) for 12 weeks Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 24 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 24 weeks |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) | Posted | Number | 95% Confidence Interval | percentage of subjects achieving SVR | 72 weeks(RBV+IFN beta), 48 weeks(MP-424+RBV+IFN beta) |
|
|
| |||||||||||||||||||||||||||||||||
| Secondary | Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response) | Posted | Number | 95% Confidence Interval | percentage of subjects achieving RVR | 4 weeks |
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response) | Posted | Number | 95% Confidence Interval | percentage of subjects achieving ETR | 48 weeks(RBV+IFN beta), 24 weeks(MP-424+RBV+IFN beta) |
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration | Posted | Number | 95% Confidence Interval | percentage of subjects achieving SVR12 | 60 weeks(RBV+IFN beta), 36 weeks(MP-424+RBV+IFN beta) |
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Transition of Serum HCV RNA Levels | Participants were excluded from analysis because of dropouts or missing data. | Posted | Median | Inter-Quartile Range | log IU/mL | Baseline，Day2，Day3，1Week，2Weeks，3Weeks，4Weeks，12Weeks，End of treatment，Follow-up 12weeks，Follow-up 24weeks |
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV. | To examine the emergence of resistance-associated variants after MP-424 administration. | "Overall number of participants analyzed" indicates the number of participants who did not achieve SVR and detected HCV RNA as positive at the last visit in each group, MP-424+RBV+IFN Beta, Genotype1 and MP-424+RBV+IFN Beta, Genotype2. | Posted | Number | participants | From baseline to 24 weeks after completion of drug administration |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | MP-424+RBV+IFN Beta, Genotype1 | "Drug: MP-424 MP-424: 750mg every 8 hours (q8h) for 12 weeks Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 24 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 24 weeks | 4 | 30 | 30 | 30 | ||
| EG001 | RBV+IFN Beta, Genotype1 | "Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 48 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 48 weeks | 3 | 30 | 30 | 30 | ||
| EG002 | MP-424+RBV+IFN Beta, Genotype2 | "Drug: MP-424 MP-424: 750mg every 8 hours (q8h) for 12 weeks Drug: RBV RBV: 600 - 1000 mg/day based on body weight for 24 weeks Drug: IFN beta IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3days /week for 24 weeks | 5 | 14 | 14 | 14 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pneumonia | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Chronic sinusitis | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Hepatocellular carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 17.1 |
| ||
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 17.1 |
| ||
| Cervix carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 17.1 |
| ||
| Anaemia | Blood and lymphatic system disorders | MedDRA ver. 17.1 |
| ||
| Cataract | Eye disorders | MedDRA ver. 17.1 |
| ||
| Optic nerve disorder | Eye disorders | MedDRA ver. 17.1 |
| ||
| Congestive cardiomyopathy | Cardiac disorders | MedDRA ver. 17.1 |
| ||
| Lung disorder | Respiratory, thoracic and mediastinal disorders | MedDRA ver. 17.1 |
| ||
| Cholangitis | Hepatobiliary disorders | MedDRA ver. 17.1 |
| ||
| Renal impairment | Renal and urinary disorders | MedDRA ver. 17.1 |
| ||
| Blood bilirubin increased | Investigations | MedDRA ver. 17.1 |
| ||
| Foot fracture | Injury, poisoning and procedural complications | MedDRA ver. 17.1 |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Cystitis | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Oral herpes | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Pharyngitis | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Herpes zoster | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Upper respiratory tract infection | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Tinea pedis | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Bronchitis | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Folliculitis | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Otitis externa | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Urinary tract infection | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Acne pustular | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Herpes virus infection | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Eczema impetiginous | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Enteritis infectious | Infections and infestations | MedDRA ver. 17.1 |
| ||
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 17.1 |
| ||
| Gastrointestinal tract adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA ver. 17.1 |
| ||
| Anaemia | Blood and lymphatic system disorders | MedDRA ver. 17.1 |
| ||
| Hyperuricaemia | Metabolism and nutrition disorders | MedDRA ver. 17.1 |
| ||
| Decreased appetite | Metabolism and nutrition disorders | MedDRA ver. 17.1 |
| ||
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA ver. 17.1 |
| ||
| Insomnia | Psychiatric disorders | MedDRA ver. 17.1 |
| ||
| Depression | Psychiatric disorders | MedDRA ver. 17.1 |
| ||
| Abulia | Psychiatric disorders | MedDRA ver. 17.1 |
| ||
| Headache | Nervous system disorders | MedDRA ver. 17.1 |
| ||
| Dizziness | Nervous system disorders | MedDRA ver. 17.1 |
| ||
| Dysgeusia | Nervous system disorders | MedDRA ver. 17.1 |
| ||
| Tension headache | Nervous system disorders | MedDRA ver. 17.1 |
| ||
| Trigeminal neuralgia | Nervous system disorders | MedDRA ver. 17.1 |
| ||
| Pingueculitis | Eye disorders | MedDRA ver. 17.1 |
| ||
| Vertigo positional | Ear and labyrinth disorders | MedDRA ver. 17.1 |
| ||
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA ver. 17.1 |
| ||
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA ver. 17.1 |
| ||
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA ver. 17.1 |
| ||
| Nausea | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Diarrhoea | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Vomiting | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Constipation | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Stomatitis | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Abdominal discomfort | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Gastritis | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Cheilitis | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Abdominal pain upper | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Faeces soft | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Dental caries | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Abdominal pain | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Colitis | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Hiatus hernia | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Periodontal disease | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Anal haemorrhage | Gastrointestinal disorders | MedDRA ver. 17.1 |
| ||
| Hepatic function abnormal | Hepatobiliary disorders | MedDRA ver. 17.1 |
| ||
| Hepatic steatosis | Hepatobiliary disorders | MedDRA ver. 17.1 |
| ||
| Rash | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Drug eruption | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Dermatitis contact | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Eczema | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Acne | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Pruritus generalised | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Eczema asteatotic | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Dermal cyst | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Dyshidrotic eczema | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Miliaria | Skin and subcutaneous tissue disorders | MedDRA ver. 17.1 |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Spinal osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Plantar fasciitis | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA ver. 17.1 |
| ||
| Renal impairment | Renal and urinary disorders | MedDRA ver. 17.1 |
| ||
| Proteinuria | Renal and urinary disorders | MedDRA ver. 17.1 |
| ||
| Renal disorder | Renal and urinary disorders | MedDRA ver. 17.1 |
| ||
| Urine abnormality | Renal and urinary disorders | MedDRA ver. 17.1 |
| ||
| Pyrexia | General disorders | MedDRA ver. 17.1 |
| ||
| Malaise | General disorders | MedDRA ver. 17.1 |
| ||
| Chills | General disorders | MedDRA ver. 17.1 |
| ||
| Oedema | General disorders | MedDRA ver. 17.1 |
| ||
| Oedema peripheral | General disorders | MedDRA ver. 17.1 |
| ||
| Chest pain | General disorders | MedDRA ver. 17.1 |
| ||
| Blood uric acid increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood creatinine increased | Investigations | MedDRA ver. 17.1 |
| ||
| Platelet count decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Hyaluronic acid increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood bilirubin increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood triglycerides increased | Investigations | MedDRA ver. 17.1 |
| ||
| White blood cell count decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Haemoglobin decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Neutrophil count decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Protein urine present | Investigations | MedDRA ver. 17.1 |
| ||
| Alanine aminotransferase increased | Investigations | MedDRA ver. 17.1 |
| ||
| Aspartate aminotransferase increased | Investigations | MedDRA ver. 17.1 |
| ||
| Haematocrit decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Red blood cell count decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Collagen antigen type IV increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood albumin decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Liver function test abnormal | Investigations | MedDRA ver. 17.1 |
| ||
| C-reactive protein increased | Investigations | MedDRA ver. 17.1 |
| ||
| Glucose urine present | Investigations | MedDRA ver. 17.1 |
| ||
| Blood chloride decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood cholesterol increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood glucose increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood pressure increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood sodium decreased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood urea increased | Investigations | MedDRA ver. 17.1 |
| ||
| Eosinophil count increased | Investigations | MedDRA ver. 17.1 |
| ||
| Blood urine present | Investigations | MedDRA ver. 17.1 |
| ||
| Thyroid function test abnormal | Investigations | MedDRA ver. 17.1 |
| ||
| White blood cell count increased | Investigations | MedDRA ver. 17.1 |
| ||
| White blood cells urine positive | Investigations | MedDRA ver. 17.1 |
| ||
| Neutrophil percentage increased | Investigations | MedDRA ver. 17.1 |
| ||
| Ligament sprain | Injury, poisoning and procedural complications | MedDRA ver. 17.1 |
| ||
| Arthropod sting | Injury, poisoning and procedural complications | MedDRA ver. 17.1 |
| ||
| Contusion | Injury, poisoning and procedural complications | MedDRA ver. 17.1 |
| ||
| Wound complication | Injury, poisoning and procedural complications | MedDRA ver. 17.1 |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Trials, Information Desk | Tanabe Pharma Corporation | cti-inq-ml.JP@ml.tanabe-pharma.com |
| ID | Term |
|---|---|
| D019698 | Hepatitis C, Chronic |
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D012254 | Ribavirin |
| D016899 | Interferon-beta |
| ID | Term |
|---|---|
| D012263 | Ribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D007370 | Interferon Type I |
| D007372 | Interferons |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
Not provided
Not provided
| Male |
|
|
|
| Participants |
|
|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Participants |
|
|